Company intelligence / Profile preview

NVMKA

Moscow, Moscow, Russia

Ownership: Private
Development stage: Other

Overview

Novumka is a clinical-stage biotechnology company focused on the development of innovative therapies for metabolic disorders, specifically type 2 diabetes mellitus. The company's lead program, NVMKA-201, is a potent and selective small molecule agonist of the G protein-coupled receptor 40 (GPR40), also known as free fatty acid receptor 1 (FFAR1). By targeting GPR40, Novumka aims to stimulate glucose-dependent insulin secretion, providing a glucose-lowering effect with a reduced risk of hypoglycemia. The company is currently advancing its lead candidate through Phase 2 clinical trials to evaluate its safety and efficacy in diabetic patients.

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on NVMKA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVMKA.

Explore the full profile